

Pre-clinical development of JSC-441, a pan-KRAS inhibitor with KRAS-SOS1 interaction inhibition mechanism

Jeil Pharmaceutical



ONCOLOGY	Preclinical
Product Type	Small molecule
Indication	KRAS mutated cancers (NSCLC, CRC, PDAC)
Target	SOS1 (Son of sevenless 1)
MoA(Mechanism of Action)	SOS1 (Son of sevenless 1) is a guanine nucleotide exchange factor (GEF) that activates the important cell signaling switch KRAS. SOS1 inhibitor blocks RAS/MAPK signaling and leads to anti-proliferative effects against all major KRAS mutants.
Competitiveness	<ul style="list-style-type: none"> (1) Among the drugs targeting KRAS mutant cancer, SOS1 inhibitors are drugs that directly target KRAS by inhibiting the KRAS-SOS1 interaction mechanism. (2) Based on the potent SOS1 inhibitory activity, the PD marker (pERK) inhibitory efficacy of the RAS/MAPK pathway is superior to competitive drugs. (3) SOS1 inhibitors show excellent tumor suppression efficacy compared to competing drugs in the KRAS mutant tumor and EGFR mutant animal efficacy evaluation model.
Development Stage	Preclinical
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.